UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
________________
| | | | | |
Filed by the Registrant x | Filed by a party other than the Registrant o |
Check the appropriate box:
| | | | | |
o | Preliminary Proxy Statement |
| |
o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| |
o | Definitive Proxy Statement |
| |
x | Definitive Additional Materials |
| |
o | Soliciting Material Pursuant to § 240.14a-12 |
| | |
Mirum Pharmaceuticals, Inc. |
|
(Name of Registrant as Specified In Its Charter) |
|
N/A |
|
(Name of Person(s) Filing Proxy Statement if other than the Registrant) |
Payment of Filing Fee (Check all boxes that apply)
| | | | | |
x | No fee required |
| |
o | Fee paid previously with preliminary materials |
| |
o | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |